ENHANCEMENT OF CD47 BLOCKADE THERAPY BY PROTEASOME INHIBITORS
CD47+ disease cells such as cancer cells are treated using a combination of CD47 blockade drug and a proteasome inhibitor. The anti-cancer effect of one drug enhances the 5 anti-cancer effect of the other. Specific combinations include SIRPαFc as CD47 blockade drug, and one of bortezomib, ixazomib and carfilzomib as proteasome inhibitor. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
1 . A use of a combination of a CD47 blockade drug and a proteasome inhibitor for treating a subject with CD47+ disease cells.
2 . The use according to claim 1 , wherein the proteasome inhibitor is selected from an epoxyketone and a boronate.
3 . The use according to claim 2 , wherein the proteasome inhibitor is a boronate.
4 . The use according to claim 3 , wherein the inhibitor is bortezomib.
5 . The use according to claim 3 , wherein the inhibitor is ixazomib.
6 . The use according to claim 2 , wherein the proteasome inhibitor is an epoxyketone.
7 . The use according to claim 5 , wherein the proteasome inhibitor is carfilzomib.
8 . The use according to claim 5 , wherein the inhibitor is a fluorinated carfilzomib analog.
9 - 47 . (canceled)